ClinicalTrials.gg
RecruitingNCT07252427Updated Jan 23, 2026

Gut Microbiota in IBD With Comorbid Depressive Disorder

An observational study in Inflammatory Bowel Disease and Depressive Disorder, sponsored by Fang Tang. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Fang Tang · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Planned enrollment
30th of 54
120 · median 148
Started
2025
with 25 others
Observational
54 of 114
21 open now
Primary completion
2027-11
later than 39 of 54 live
Registered
92nd of 114
by date

Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 30th largest by planned enrollment of the 54 observational ones that give a count, is one of 26 that started in 2025, is one of 54 observational ones, reaches primary completion later than 39 of the 54 other live ones, and was the 92nd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

Inflammatory bowel disease (IBD) is often comorbid with depressive disorder, and the development and progression of both conditions are closely related to the composition of gut microbiota and metabolites. However, studies investigating their comorbidity using microbiome and metabolomics approaches remain limited.

This study aims to investigate the diversity changes in the gut microbiome and metabolome of patients with comorbid IBD and depressive disorder through multi-omics approaches, to identify specific microbial and metabolic signatures associated with the comorbidity of these two conditions, and to provide a molecular basis for elucidating the underlying mechanisms.

Read the detailed description

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that significantly impairs patients' quality of life. Depressive disorder is a common comorbidity in patients with IBD, and the coexistence of the two conditions can exacerbate disease burden and complicate treatment management. Increasing evidence suggests that both IBD and depressive disorder are closely related to alterations in the gut microbiome and metabolome; however, studies focusing on the comorbidity of these two conditions using multi-omics approaches remain limited.

This cross-sectional observational study aims to investigate the diversity and compositional changes of the gut microbiome and metabolome in patients with comorbid IBD and depressive disorder. Fecal, blood, and intestinal mucosal samples will be collected from three groups: (1) patients with IBD and comorbid depressive disorder, (2) patients with IBD without depressive disorder, and (3) control group. Through multi-omics analysis, the study seeks to identify specific microbial taxa and metabolites associated with the comorbidity of IBD and depressive disorder, uncover differential microbial and metabolic profiles among the three groups, and explore the potential molecular mechanisms underlying the interaction between intestinal inflammation and depressive symptoms. The findings are expected to provide a scientific basis for the development of novel diagnostic biomarkers and therapeutic strategies for IBD patients with comorbid depressive disorder.

03

Conditions studied

  • Inflammatory Bowel Disease
  • Depressive Disorder

Keywords

  • Inflammatory Bowel Disease
  • Depressive Disorder
  • Comorbidity
  • Gut Microbiome
  • Metabolomics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with inflammatory bowel disease with or without comorbid depressive disorder, and control participants, recruited from the First Affiliated Hospital of Shandong First Medical University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

IBD with Depressive Disorder Group:

  1. Patients diagnosed with inflammatory bowel disease (ICD-10 codes: K50-K51).
  2. History of depressive disorder diagnosis or previous use of antidepressant medications.
  3. Age ≥ 18 years.
  4. Willingness to participate and provision of written .

IBD without Depressive Disorder Group:

  1. Patients diagnosed with inflammatory bowel disease (ICD-10 codes: K50-K51).
  2. No history of depressive disorder diagnosis
  3. No previous use of antidepressant medications.
  4. Age ≥ 18 years.
  5. Willingness to participate and provision of written informed consent.

Control Group:

  1. No history of inflammatory bowel disease, depressive disorder, or use of antidepressant medications.
  2. No gastrointestinal symptoms (e.g., diarrhea, constipation, abdominal pain) within the past 3 months, and no history of gastrointestinal diseases.
  3. Age ≥ 18 years.
  4. Willingness to participate and provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Presence of other major chronic diseases or infections (e.g., , hypertension, diabetes, coronary heart disease).
  2. Use of antibiotics or probiotic supplements within the past 6 months.
  3. Inability or difficulty in providing biological samples.
  4. Missing essential patient information.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • IBD with Depressive Disorder Group

    Other: Not applicable- observational study

  • IBD without Depressive Disorder Group

    Other: Not applicable- observational study

  • Control Group

    Other: Not applicable- observational study

Interventions

  • OtherNot applicable- observational study

    observational study with no assigned intervention

06

What researchers measure

Primary outcomes

  1. Gut microbiota composition and relative abundance

    The primary outcome is the expression level and diversity of gut microbial taxa identified through metagenomic analysis among the three study groups.

    Time frame: Baseline

Secondary outcomes

  1. Metabolite profiles and relative abundance

    The secondary outcome is the expression level and diversity of serum and fecal metabolites identified through untargeted metabolomics analysis, and their correlations with gut microbial composition.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2027, 32 months after the start.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 32 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 26, 2025
StartActual
Mar 16, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07252427
Lead sponsor
Fang Tang
Responsible party
Fang Tang (Doctor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Nov 26, 2025
Start date
Mar 16, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jan 23, 2026
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion